Iran Presents Medical Plasma and Radiopharmaceutical Capabilities in Vienna

## Iranian expertise showcased alongside IAEA conference

The Atomic Energy Organization of Iran presented products and technical and engineering services in medical plasma and radiopharmaceuticals at a side event held in Vienna alongside the 70th General Conference of the International Atomic Energy Agency (IAEA).

The event, titled “Presentation of Products and Technical and Engineering Services in the Fields of Medical Plasma and Radiopharmaceuticals,” was held on Tuesday, 24 Shahrivar, with participants from several countries. The gathering provided a platform for Iranian specialists to outline the activities of two companies associated with the country’s nuclear technology sector: Plasma Technology Development Company and Pars Isotope.

According to the Iranian Students’ News Agency (IRNA), experts from the two companies presented selected recent achievements, available services, clinical research findings, radiopharmaceutical products and future plans.

## Focus on medical plasma and radiopharmaceuticals

The presentations covered two areas with direct applications in healthcare. Medical plasma technologies can support research and treatment-related services, while radiopharmaceuticals are used in diagnostic, therapeutic and palliative applications.

The Iranian delegation described the capabilities and services developed by the participating companies, as well as the results of clinical investigations. It also outlined the radiopharmaceutical portfolio of Pars Isotope and discussed the company’s plans for future development.

The event was intended not only to present individual products but also to introduce broader Iranian capacities in nuclear science and technology. Participants were briefed on the work of Iranian specialists in fields described by the organizers as scientific and emerging areas.

IRNA reported that attendees praised the progress of Iranian experts after learning about the country’s achievements and capabilities. The report did not identify the participants who made those comments or provide independent technical assessments of the products and research findings presented.

## Exhibition of nuclear-industry achievements

A separate exhibition of Iran’s nuclear-industry achievements was also opened on the sidelines of the IAEA conference in Vienna on the same day. Specialists and experts introduced visitors to Iranian capabilities across nuclear science and technology, with particular attention to plasma technology and diagnostic, therapeutic and palliative radiopharmaceuticals.

The exhibition complemented the scientific and technical presentations by offering visitors an opportunity to learn about the products and services directly from Iranian representatives. The evidence available for this report does not specify the number of exhibits, the organizations represented beyond the companies named, or whether any commercial, research or cooperation agreements were concluded during the event.

## Part of the IAEA General Conference

The 70th regular session of the IAEA General Conference began in Vienna on Monday, 23 Shahrivar, with the participation of the agency’s member states. According to the report, senior officials and representatives were expected to examine issues related to the agency’s activities and budget and to take decisions on those matters.

Iran’s side event took place within this wider diplomatic and technical setting. At the conclusion of the program, speakers from the Atomic Energy Organization of Iran answered questions from attendees about Iran’s activities in nuclear science and technology.

The Vienna presentations therefore served both as a technical showcase and as an opportunity for Iranian representatives to explain aspects of the country’s nuclear-health capabilities to an international audience. The available account emphasizes the presentation of products, services, research results and future plans, while providing no detailed data on clinical outcomes, production volumes, regulatory approvals or international partnerships.